Patents Assigned to Janssen Sciences Ireland Unlimited Company
-
Patent number: 11918575Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.Type: GrantFiled: December 2, 2021Date of Patent: March 5, 2024Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
-
Patent number: 11866419Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.Type: GrantFiled: September 17, 2021Date of Patent: January 9, 2024Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
-
Patent number: 11780900Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.Type: GrantFiled: April 24, 2019Date of Patent: October 10, 2023Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Yue-Mei Zhang, Raul Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
-
Patent number: 11713345Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.Type: GrantFiled: October 22, 2019Date of Patent: August 1, 2023Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
-
Patent number: 11708369Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.Type: GrantFiled: April 19, 2019Date of Patent: July 25, 2023Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérome Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Peter Rigaux, Antoine Benjamin Michaut, Sabrina Dany France Quatrevaux, Sovy Chao, Dirk André Emmy Roymans
-
Patent number: 11702426Abstract: This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.Type: GrantFiled: October 27, 2020Date of Patent: July 18, 2023Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANYInventors: Jean-François Bonfanti, Jérôme Michel Claude Fortin, Philippe Muller, Frédéric Marc Maurice Doublet, Pierre Jean-Marie Bernard Raboisson, Eric Pierre Alexandre Arnoult
-
Patent number: 11597704Abstract: This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy.Type: GrantFiled: February 28, 2019Date of Patent: March 7, 2023Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANYInventors: David Craig Mc Gowan, Werner Constant Johan Embrechts, Jérôme Émile Georges Guillemont, Ludwig Paul Cooymans, Tim Hugo Maria Jonckers, Pierre Jean-Marie Raboisson
-
Patent number: 11564921Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.Type: GrantFiled: July 18, 2018Date of Patent: January 31, 2023Assignees: ViiV Healthcare Company, Janssen Sciences Ireland Unlimited CompanyInventors: Herta Crauwels, David Margolis, William R. Spreen, Andrew Spaltenstein, Peter Williams
-
Patent number: 11491157Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).Type: GrantFiled: January 30, 2019Date of Patent: November 8, 2022Assignee: Janssen Sciences Ireland Unlimited Company Co Cork, IEInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut
-
Patent number: 11491148Abstract: The application relates to amide derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection:Type: GrantFiled: May 5, 2020Date of Patent: November 8, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Bart Rudolf Romanie Kesteleyn, Jan Martin Berke, Erwin Coesemans, Sandrine Céline Grosse, Edgar Jacoby, Tim Hugo Maria Jonckers, Stefaan Julien Last, Wim Gaston Verschueren, Michel Obringer, Christelle Catherine Cecile Doebelin
-
Patent number: 11427599Abstract: The present invention relates to an improved process for preparing [(1S,2R)-3-[[(4-aminophenyl)-sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester—which compound is also known under its INN as darunavir—by reacting carbonic acid 2,5-dioxo-1-pyrrolidinyl [(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]ester with 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-benzenesulfonamide in ethanol as solvent. Furthermore said process allows for darunavir to be isolated immediately in its ethanolate form, i.e. darunavir monoethanolate, which is the marketed form of darunavir under the tradename Prezista™.Type: GrantFiled: September 14, 2020Date of Patent: August 30, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Alfred Elisabeth Stappers, Yolande Lydia Lang, Shane Barry Robinson
-
Patent number: 11395867Abstract: A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings.Type: GrantFiled: June 30, 2020Date of Patent: July 26, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Lieven Elvire Colette Baert, Iksoo Chun, Guenter Kraus, Deborah M. Schachter, Qiang Zhang
-
Patent number: 11389531Abstract: Methods and apparatus for the reproducible, consistent and efficacious delivery of an HBV vaccine to a subject. The disclosure comprises apparatus for the controlled administration of the HBV vaccine through an orifice to the subject, a plurality of penetrating electrodes arranged with a predetermined spatial relationship relative to the orifice, and an electrical signal generator operatively connected to the electrodes.Type: GrantFiled: December 18, 2018Date of Patent: July 19, 2022Assignees: Janssen Sciences Ireland Unlimited Company, Ichor Medical Systems, Inc.Inventors: Daniel Boden, Helen Horton, Jean-Marc Edmond Fernand Marie Neefs, Soumitra Roy, Andrew W. Hannaman, Robert M. Bernard, Stephen A. Morse, Oliver Ruck, Adam Hartman, Thomas David Cox, Dorien De Pooter
-
Patent number: 11389447Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.Type: GrantFiled: December 9, 2015Date of Patent: July 19, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Lieven Elvire Colette Baert, Willy Albert Maria Carlo Dries, Laurent Bruno Schueller, Marc Karel Jozef Francois, Peter Jozef Maria Van Remoortere
-
Patent number: 11369612Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.Type: GrantFiled: December 4, 2018Date of Patent: June 28, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André Emmy Roymans, Anil Koul
-
Patent number: 11339165Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).Type: GrantFiled: November 28, 2018Date of Patent: May 24, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut, Guillaume Jean Maurice Mercey
-
Publication number: 20220088012Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.Type: ApplicationFiled: December 2, 2021Publication date: March 24, 2022Applicant: Janssen Sciences Ireland Unlimited CompanyInventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
-
Patent number: 11253479Abstract: Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent.Type: GrantFiled: October 27, 2017Date of Patent: February 22, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventor: Daniel Joseph Christiaan Thoné
-
Patent number: 11224596Abstract: The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.Type: GrantFiled: February 28, 2018Date of Patent: January 18, 2022Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Maria Cristina Villellas Arilla
-
Patent number: 11220504Abstract: This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.Type: GrantFiled: April 12, 2019Date of Patent: January 11, 2022Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANYInventors: David Craig McGowan, Stefaan Julien Last, Serge Maria Aloysius Pieters, Werner Embrechts, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson